Pakistan to conduct phase-III clinical trial of COVID-19 vaccine in collaboration with Chinese company
Published
National Institute of Health (NIH) said in a statement that it has obtained "formal approval" from the Drug Regulatory Authority of Pakistan (DRAP) for phase-III Clinical Trial of Recombinant Novel Coronavirus Vaccine Adenovirus Type 5 vector (Ad5-nCoV) developed by CanSinoBio and Beijing Institute of Biotechnology China (BIB).
Full Article